Rheumatology

Article	Citations
P070 Evaluation of the perception of pediatric rheumatology by pediatric residents: results of a national survey	100
P137 Epidemiological study of influenza vaccination and RA	95
P205 The contemporary presentation and management of giant cell arteritis with large vessel vasculitis	94
Cardiovascular risk and mortality in rheumatoid arthritis compared with diabetes mellitus and the general population	92
67 Double impact: hypophosphatemic rickets and vitamin D intoxication	82
P018 Non-alcoholic fatty liver disease in spondyloarthritis: identifying patients on therapy at high risk of serious liver disease	81
P103 The impact of the COVID-19 pandemic on primary care referrals and new diagnoses of inflammatory arthritis	73
E053 Effectiveness of colchicine among patients with COVID-19 infection: a randomised, open labelled, clinical trial	72
E010 Checkpoint inhibitor-induced rheumatological adverse events: real-world experience from Northeast England	72
E078 Inflammation modifies the effect of rheumatoid arthritis in overall mortality among females	67
OA02 Real-world experience of dose tapering TNF inhibitors in rheumatoid arthritis: Long-term results	65
P107 Long-term efficacy of baricitinib in patients with rheumatoid arthritis with inadequate response to bDMARDs: results from RA-BEYOND up to 6.9-years of treatment	58
P186 Long-term safety of ixekizumab in adult patients with psoriasis, psoriatic arthritis, and axial spondyloarthritis	58
P110 Challenges of meeting NICE guidance for rheumatoid arthritis in the modern era: a service audit	53
P045 Development and evaluation of machine learning algorithms for the prediction of opioid-related deaths among UK patients with non-cancer pain	52
E063 Cardiac amyloidosis: a case series of 31 patients with a comprehensive literature review	50
E058 The effects of a pain management programme for patients with an inflammatory arthritis	50
P139 Rituximab in a large UK centre during the COVID-19 pandemic: the effects of employing a reduced dosing regimen on clinical response in Rheumatoid Arthritis patients	48
P193 Bimekizumab improves key symptoms, disease activity and function in patients across the full spectrum of axial spondyloarthritis up to week 24: results from two phase 3 studies	47
P007 Automating blood monitoring and handover for patients with rheumatic diseases commencing disease-modifying anti-rheumatic drugs (DMARDs)	47
P166 Parotid benign lymphoepithelial cyst in connective tissue disease: a rare case series and literature review	47
P104 The role of occupational therapy for the self-management of rheumatoid arthritis: a mixed methods systematic review	47
P071 Exercise as an anti-inflammatory treatment in axial spondyloarthritis (axSpA): a proof-of-concept study	47
E027 An outlandish presentation of IgG4-related disease	46
P012 Using the BSR Lupus audit as a springboard to improve management of SLE in the outpatient clinic	46

P068 The effects of exercise and physical activity in inflammatory rheumatic diseases: a scoping literature review	44
P054 Utilising a pharmacist-designed best value biologic and targeted synthetic shared decision-making tool to empower patients, support clinicians and save NHS resources	44
P010 Real world experience of switching to an adalimumab biosimilar; different outcomes for axial spondylitis, psoriatic and rheumatoid arthritis	43
P105 Mode of hospital rheumatology appointments in people with rheumatoid arthritis: the impact of the pandemic in England	42
P183 Disease activity, comorbidities and functional status predict treatment response to biologic and targeted synthetic disease-modifying anti-rheumatic drugs in psoriatic arthritis	42
P124 Rheumatoid Arthritis with Normal CRP: an Underappreciated, Persistent Phenotype: Equally at Risk of Severe Disease	42
OA03 Harnessing quantitative proteomics to identify biomarkers of treatment response to etanercept in patients with rheumatoid arthritis	41
P095 Fibromyalgia correlates with neurodivergent traits in a self-selected community population	41
P053 Patient engagement in long-term PROMs collection: 48-month observation in real-world clinical practice	41
P198 Intracardiac thrombosis and vascular involvement in Behçet's disease: two sides of the same coin?	40
OA17 Patient values and what matters to patients with axial spondyloarthritis in clinic	40
P127 Baricitinib Efficacy in Moderate Rheumatoid Arthritis - A Post-hoc Analysis from two Phase III Trials	38
E011 What information should we provide to inform and empower our patients to participate in shared decision making? The patient perspective	38
OA32 Jaw claudication - does the textbook description need updating?	38
E072 Real-world single-centre experience of JAK inhibitor use in RA	38
P056 Analysis of antibody response to SARS-CoV-2 vaccination and natural infection in a tertiary centre cohort of lupus nephritis patients	38
P086 Service evaluation of ultrasound use in patients with juvenile idiopathic arthritis in a UK tertiary paediatric rheumatology centre, as the first step towards developing an evidence-based guideli	36
P070 Results of a consensus process to determine the elements of a complex digital intervention for distal upper limb musculoskeletal disorders	36
P072 Significant functional impairment and disability in individuals with psoriatic arthritis and Achilles tendon pain	35
P195 Use of the Giant Cell Arteritis Score (GCAPS) in a district general hospital	35
E082 A review of the development of gangrene in patients with systemic lupus erythematosus: a 44-year follow-up study	34
P058 Pneumocystis Jirovecii Infection in autoimmune inflammatory rheumatic diseases in Oxford	33
P043 Income-Related Health Inequality and Osteoarthritis Intervention Outcomes: a Cohort Study	33
P082 Research priorities regarding the use of bisphosphonates for osteoporosis: a UK priority setting exercise	33
E049 The Initial Impacts of the UK-Wide Rheumatology Physiotherapy Capabilities Framework	33
P148 Long-term survival of patients with idiopathic inflammatory myopathies: Anatomy of a single-center cohort	33
P009 Navigating giant cell arteritis (GCA) service during and post COVID-19 pandemic: an audit of GCA care at North Bristol NHS Trust against the BSR quality standards	33
Comment on: Association of serum levels of inflammatory markers and adipokines with joint symptoms and structures in participants with knee osteoarthritis: reply	32
O08 Developing a DNA methylation signature for predicting rheumatoid arthritis using a machine learning pipeline	32
O14 Frequency and site of clinically unsuspected synovitis on whole-body MRI in juvenile idiopathic arthritis	32
A 72-year-old man with life-threatening dyspnoea due to a neck mass of unexpected origin	31
Trends in risk factor control in patients with gout: data from the National Health and Nutrition Examination Survey, 2007–2018	31
Is adipose-tissue (or its fraction) grafting really effective in the treatment of scleroderma hand?	30
Reliability assessment of the definition of ultrasound enthesitis in SpA: results of a large, multicentre, international, web-based study	30
Sicca syndrome in systemic sclerosis: a narrative review on a neglected issue	30
Diagnosing giant cell arteritis: a comprehensive practical guide for the practicing rheumatologist	29
Comment on: Refining myositis associated with primary Sjögren’s syndrome: data from the prospective cohort ASSESS	29
P069 Assessment of diagnostic delay for hip disorders in the pediatric population	28
P133 NICE Guidance 41: Is it applicable to a real-world cohort of cervical spine fractures in older people?	28
P076 SARS-COV-2 infection in two patients with juvenile lupus	28
P263 Autoantibodies in ankylosing spondylitis: a systematic literature review	28
P143 Frailty is associated with inflammation, impaired glucose metabolism and reduced bone mineral density after adjustment for fat mass index: a UK biobank study	27
P120 A collaborative approach to rolling out advice and guidance	27
P239 Are patients with acute pericardial syndromes adequately screened for connective tissue diseases? Results from a single-centre study and comparison to European Society of Cardiology Guidelines	27
OA20 Radiographic hip osteoarthritis classified semi-automatically on dual-energy x-ray absorptiometry scans is strongly predictive of total hip replacement: findings from UK Biobank	27
OA02 A cohort of 79 children with Paediatric multisystem inflammatory syndrome associated with COVID-19	27
P299 What happens if the rheumatologist is no longer the gatekeeper to temporal artery ultrasound in giant cell arteritis?	26
P179 A feasibility randomised controlled trial of a fibromyalgia self-management programme in a community setting with a nested qualitative study	26
P085 NRAS New2RA Right Start for people newly/recently diagnosed with RA	26
P019 Rheumatology Referrals to Tertiary Care Hospital over a Three Month Period During Covid-19 Pandemic: a Quality Improvement Project	26

P305 Validating diagnostic GCA ultrasonography skills against an expert sonographer	26
P207 NRAS Virtual Groups	26
P065 Post COVID-19 vaccination inflammatory arthritis: a case series of patients at a district general hospital	25
P025 Do referrals to rheumatology meet the new British Society of Rheumatology (BSR) guidelines for adult patients with osteoporosis? A retrospective audit of a tertiary osteoporosis service	25
P146 Hepatitis E infection in rheumatic disease: no evidence of chronicity	25
P185 Patients' and clinicians' perspectives on the clinical utility of the Rheumatoid Arthritis Foot Disease Activity Index	25
P077 Developing a better explanation of osteoarthritis: results from a conjoint analysis of patient preferences	25
P086 Patient perceptions of musculoskeletal ultrasound as an educational tool in a rheumatology podiatry clinic	25
P029 Evaluating the uptake and impact of National Institute for Health and Care Excellence guidance on arthritis	25
P089 Patient-reported outcome measures for rheumatoid arthritis disease activity: a systematic review following COSMIN guidelines	25
Pauci-immune synovitis in other inflammatory arthritides: it’s not just a subtype of rheumatoid arthritis that is unresponsive to treatment	24
P126 GCA Hospital Standards (GHOST) - making a map of specialised services for the care of giant cell arteritis across England	24
Anti-C1q antibodies in IgG4-related disease are common and associated with renal involvement and cutaneous small-vessel vasculitis	24
OA04 COVID-19 admissions and mortality in patients with early inflammatory arthritis: results from a national cohort	24
P141 What are the predictors of fragility fracture in patients with low body mass index: an observational cohort study	24
Corrigendum to: Comparative study of obstetric antiphospholipid syndrome (OAPS) and non-criteria obstetric APS (NC-OAPS): report of 1640 cases from EUROAPS registry	24
P101 Estimating the quality of life and economic impact of arthritis in Tanzania	24
P156 Multidisciplinary paediatric rheumatology clinics	24
Combined radiographic and US evaluations to decipher joint involvement in the hands of patients with SSc	23
Extracorporeal membrane oxygenation for life-threatening ANCA-associated vasculitis with pulmonary haemorrhage	23
Optical spectral transmission to monitor disease activity in arthritis patients: longitudinal follow-up comparison with clinical parameters	23
P060 Pilot study showing the efficacy and acceptability of an acceptance and commitment therapy based brief psychological intervention on mood and disability in patients with early inflammatory arthri	23
P038 Let’s look at coxitis features in enthesitis-related arthritis population	23
P119 Average percent fat is associated with decreased bone mineral density at the hip but increase at the spine longitudinally, where weight shows a positive association at all anatomical locations	23
Impact of incident rheumatoid arthritis on earnings: a nationwide sibling comparison study	23
Neuropsychiatric systemic lupus erythematosus in a girl with neurocutaneous melanosis caused by a somatic mutation in NRAS	22
P089 The cost of repeat ANA testing in north west London pathology services	22
P051 Juvenile Behcet's disease	22
P010 Clinico-epidemiological characteristics and outcomes of Juvenile Idiopathic Arthritis (JIA) patients in Kenya: data from the KAPRI registry	22
Comment on: ANCA in systemic sclerosis, when vasculitis overlaps with vasculopathy: a devastating combination of pathologies	22
Comment on: Obstetric antiphospholipid syndrome is not associated with an increased risk of subclinical atherosclerosis. Reply	22
Systemic sclerosis and cancer in the UK: an epidemiological analysis using the clinical practice research datalink	22
A deeper dive into rare autoimmune diseases, death and COVID-19 in the first wave of the pandemic	22
The global epidemiology of SLE: narrowing the knowledge gaps	22
P035 Hip involvement in Tunisian Juvenile Idiopathic Arthritis patients	22
Hypocomplementemic urticarial vasculitis syndrome revealed by bilateral sudden sensorineural hearing loss	22
OA34 Post-hoc analysis of spinal MRI SPARCC inflammation scores in patients with radiographic axial spondyloarthritis treated with ixekizumab: results from the COAST-V study at week 16	21
OA28 Exploring the potential of polygenic risk scores for predicting coronary artery disease in patients with rheumatoid arthritis	21
P218 Drug repurposing screen of Food and Drug Administration-approved medicines identifies novel anti-inflammatory and NF-kB inhibitory activity of the tyrosine kinase inhibitor sunitinib malate	21
P064 Henoch-Schonlein Purpura: experience of a general pediatric center	21
P131 Adult coeliac disease and bone mineral density at the femoral neck, total hip and lumbar spine: an age- and sex-matched case-control study	21
P204 Filgotinib demonstrates clinical efficacy in rheumatoid arthritis independent of smoking status: a post-hoc subgroup analysis of three Phase 3 clinical trials	21
P121 Using patient experiences to redesign health provision - is this the future of rheumatology services?	21
P162 Incidence of neutropaenia and infections in lupus patients on immunosuppression	21
P138 Real-world incidence and management of hypocalcaemia after denosumab administration in patients with chronic kidney disease: a UK secondary-care based audit	21
P142 Fracture risk in diabetes: to FRAX or not to FRAX?	21
P280 Maternal use of hydroxychloroquine with anti-Ro and or anti-La during pregnancy: a systematic review	21
P083 Undergraduate rheumatology teaching in the UK: a survey of teachers	20
P031 Adherence with Methotrexate in Tunisian Juvenile Idiopathic Arthritis Patients	20
OA06 Clinical outcomes of filgotinib in patients with rheumatoid arthritis aged ≥65 years: a post hoc subgroup analysis of Phase 2 and 3 clinical trials and ongoing long-term extensions	20
P169 A validated two-score system for interferon is a predictor of response to rituximab in SLE	20
P042 Using a Genetic PROBability tool (G-PROB) to aid diagnosis of patients with inflammatory arthritis: results from the Norfolk Arthritis Register	20
P117 Exploring experiences of Fracture Liaison Services and perceptions of a new decision tool to support patient and clinician decisions: a focus group study	20
An unusual case of neck pain: crowned dens syndrome	20
P025 Risk assessment of covid 19 in patients with Juvenile Idiopathic Arthritis	20
O13 Which composite measure best reflects disease activity and predicts treatment change in psoriatic arthritis?	20
P107 Improving care for people with chronic low back pain - ESCAPE-pain for back	20
Evidence and consensus-based recommendations for non-pharmacological treatment of fatigue, hand function loss, Raynaud’s phenomenon and digital ulcers in patients with systemic sclerosis	20
Independent associations of lymphopenia and neutropenia in patients with systemic lupus erythematosus: a longitudinal, multinational study	20
Comment on: The sFlt-1 to PlGF ratio in pregnant women with rheumatoid arthritis: impact of disease activity and sulfasalazine use. Reply	20
COVID-19 and mortality in rare rheumatic diseases, a warning bell?	20
OA44 Increasing access to rehabilitation for knee and hip osteoarthritis - ESCAPE-pain in leisure/community centres	20
Hypothyroidism in vasculitis	20
SNP-based heritability estimates of gout and its subtypes determined by genome-wide association studies of clinically defined gout	20
Corrigendum to: Patient and Rheumatologist Perspectives on Tapering DMARDs in Rheumatoid Arthritis: A Qualitative Study	19
Work participation is unaffected in Belgian spondyloarthritis patients: data from the BelGian Inflammatory Arthritis and SpoNdylitis cohorT	19
P144 Socioeconomic deprivation is associated with reduced response and lower treatment persistence with anti-TNF therapies in people with rheumatoid arthritis	19
Etanercept originator versus etanercept biosimilar for the treatment of rheumatoid arthritis as a first biologic: results from the BSRBR-RA	19
Measurement of specific organ domains in lupus randomized controlled trials: a scoping review	19
P128 A subgroup analysis of the efficacy of filgotinib for patients with moderately active RA following an inadequate response to methotrexate	19
Adherence to dietary guidelines, and the risk of developing rheumatoid arthritis: results from a nested case-control study	19
Correction to: Vision transformer assisting rheumatologists in screening for capillaroscopy changes in systemic sclerosis: an artificial intelligence model	19
Comment on: Detection of a rare variant in PSTPIP1 through three generations in a family with an initial diagnosis of FMF/MKD-overlapping phenotype	19
Assessment and diagnosis of the acute hot joint: a systematic review and meta-analysis	19
Allelic expression imbalance in articular cartilage and subchondral bone refined genome-wide association signals in osteoarthritis	19
OA16 Therapeutic certolizumab pegol drug levels to achieve good EULAR response in patients with rheumatoid arthritis: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syn	19
Impact of COVID-19 and COVID-19 vaccination on high-risk patients with antiphospholipid syndrome: a nationwide survey	19
Association of anti-TPM4 autoantibodies with vasculopathic cutaneous manifestations in juvenile dermatomyositis	19
The clinical phenotype of systemic sclerosis patients with anti-PM/Scl antibodies: results from the EUSTAR cohort	19
Comment on: Beneficial effects of nintedanib on cardiomyopathy in patients with systemic sclerosis: a pilot study	19

P180 Undiagnosed depression in axial spondyloarthropathy negatively affects disease activity and quality of life	19
The COMPARE head-to-head, randomized controlled trial of SEL-212 (pegadricase plus rapamycin-containing nanoparticle, ImmTOR™) versus pegloticase for refractory gout	19
COVID-19 vaccine hesitancy in inflammatory arthritis patients: serial surveys from a large longitudinal national Australian cohort	19
Comparison and validation of FDG-PET/CT scores for polymyalgia rheumatica	19
OA34 Unravelling the role of B cells and interferon dysregulation in juvenile dermatomyositis	19
P210 Tocilizumab versus prednisolone only treatment for giant cell arteritis: an observational study	19
All-cause and cause-specific mortality in patients with giant cell arteritis: a nationwide, population-based cohort study	19
The synergistic efficacy of hydroxychloroquine with methotrexate is accompanied by increased erythrocyte mean corpuscular volume	19
Disappearance of bilateral adrenal tumours: immunodeficiency-associated lymphoproliferative disorder in a patient with rheumatoid arthritis	18
P080 BSR national training survey results for rheumatology and GIM dual-accreditation	18
P196 Secukinumab provides sustained improvements in subgroup analyses of joint tenderness and swelling in patients with psoriatic arthritis: 5year results from the Phase3 FUTURE 2 study	18
Tocilizumab-induced organizing pneumonia in a patient with systemic sclerosis–associated interstitial lung disease	18
Characteristics of patients with difficult-to-treat rheumatoid arthritis in a French single-centre hospital	18
ANCA in systemic sclerosis, when vasculitis overlaps with vasculopathy: a devastating combination of pathologies	18
Central retinal vein and cilioretinal artery occlusion in a case of systemic sclerosis treated with a JAK inhibitor figlotinib	18
Diagnosing and managing dysphagia in inclusion body myositis: a systematic review	18
Therapeutic dilemmas in relapsing renal ANCA-associated vasculitis	18
Hydroxychloroquine-related hyperpigmentation	18
Call for emergency action to limit global temperature increases, restore biodiversity and protect health	18
The impact of 2023 EMA recommendations on patients treated with JAK inhibitors: real-life experience from a prospective monocentric cohort	18
Regional differences in clinical phenotype of axial spondyloarthritis: results from the International Map of Axial Spondyloarthritis (IMAS)	18
Granulomatosis with polyangiitis presenting as obstructive uropathy and vasculitic myopathy	18
O007. Register of hereditary auto-inflammatory diseases in a pediatric rheumatology unit	18
P028 Impact of Juvenile Idiopathic Arthritis on schooling	18
P096 Pregnancy outcomes in women attending a joint obstetric and rheumatology clinic in a tertiary centre over a 2-year period	18
What we know and what we don’t know about catastrophic antiphospholipid syndrome	18
Obinutuzumab as treatment for ANCA-associated vasculitis	18
Effects of interleukin-6 signal inhibition on Treg subpopulations and association of Tregs with clinical outcomes in rheumatoid arthritis	18
The 2022 British Society for Rheumatology guideline for the treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs	18
OA04 Impact of pre-operative and perioperative parental preparation on the success of surgery in Tunisian children with scoliosis	17
E56 A 16-year diagnosis delay of a patient with Pigmented Villonodular Synovitis	17
E42 Severe infectious adverse events in children treated with biological agents	17
E08 Single center study of Systemic Juvenile Idiopathic Arthritis in Moroccan patients	17
Tapentadol effects on brain response to pain in sensitized patients with knee osteoarthritis	17
Anti-Ro52 antibodies are associated with the prognosis of adult idiopathic inflammatory myopathy-associated interstitial lung disease	17
E15 Immunopositive and immunonegative juvenile idiopathic arthritis: what makes the difference?	17
E37 Clinical and demographic criteria of Juvenile primary systemic vasculitis in Libyan Children	17
E12 Sleep disturbance among Juvenile idiopathic arthritis patients	17
E60 Localized scleroderma and venous thrombosis: an uncommon association in a case report	17
Fully automated opportunistic screening of vertebral fractures and osteoporosis on more than 150 000 routine computed tomography scans	17
Medication adherence in older people with rheumatoid arthritis is lower according to electronic monitoring than according to pill count	17
E40 Chronic recurrent multifocal osteomyelitis: management disease in Tunisian child population	17
E62 Paediatric rheumatology cases at department of physical medicine/rheumatology Victoria hospital over nine years	17
E17 Juvenile idiopathic arthritis: are girls less lucky?	17
P047 Musculoskeletal symptoms as first clinical presentation of juvenile-onset systemic lupus erythematosus: Experience from a military internal medicine department	17
Serum IFNα2 levels are associated with disease activity and outperform IFN-I gene signature in a longitudinal childhood-onset SLE cohort	17
E06 Does GGT level correlate with activity parameters in enthesitis-related arthritis?	16
Comment on: Muscle involvement in systemic lupus erythematosus: multimodal ultrasound assessment and relationship with physical performance: reply	16
E44 Differences of hematological abnormalities between COVID-19 infection and multisystemic inflammatory syndrome (MIS-C)	16
P010 Management of fibromyalgia patients in secondary care: a retrospective audit	16
Machine learning–driven immunophenotypic stratification of mixed connective tissue disease, corroborating the clinical heterogeneity	16
E30 Sequelae of Juvenile Idiopathic Arthritis in a 20-year-old young woman	16
Cholesterol crystals in rheumatoid bursal fluid	16
P053 The place of ASLOs in the diagnosis of RAA in Morocco	16
Shielding reduced incidence of COVID-19 in patients with inflammatory arthritis but vulnerability is associated with increased mortality	16
P061 Patient experience of telephone helpline service during the COVID-19 pandemic	16
COVID-19 mRNA vaccine immunogenicity decay and breakthrough illness in adolescents and young adults with childhood-onset rheumatic diseases	16
Clinical vignette: paraneoplastic diffuse systemic sclerosis	16
P030 Impact of methotrexate on growth in children with Juvenile Idiopathic Arthritis	16
P076 Adherence to COVID-19 risk stratification during the peak of pandemic: a District General Hospital experience	16
P139 The impact of identifying poor adherence to bone protective treatment via postal questionnaire - Bath Fracture Liaison Service (FLS) audit	16
The role of IL-23 in joint disease	15
Pathogenetic associations of anti-ribosomal P protein antibody titres and their subclasses in patients with systemic lupus erythematosus	15
Genetically proxied IL-1 receptor antagonism and risk of polymyalgia rheumatica	15
Can the dose of belimumab be reduced in patients with systemic lupus erythematosus?	15
Early-onset stroke and iron-deficiency anaemia in young siblings	15
Comment on: Significance of PR3-ANCA positivity in eosinophilic granulomatosis with polyangiitis (Churg–Strauss)	15
Let’s talk about shoulder osteoarthritis	15
P030 Antiphospholipid syndrome and giant cell arteritis: a coincidence or connection?	15
Fourth dose of BNT162b2 vaccine for patients with autoimmune rheumatic diseases in a nationwide setting	15
Boxer’s shape, an unusual finding in nailfold capillaroscopy	15
Correction to: Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus	15
P159 Factors associated between SLE and work amongst South Asian people: an explorative qualitative study	15
P152 The incidence of anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies may be higher than we think	15
Prescribing anti-rheumatic drugs in pregnancy and breastfeeding—the British Society for Rheumatology guideline scope	15
Identification of new candidate drugs for primary Sjögren’s syndrome using a drug repurposing transcriptomic approach	15
Useful alternative drugs before the use of opioids in patients with allergy to NSAIDs	15
Dry gangrene in cold agglutinin syndrome	15
P190 Secukinumab improves back pain, morning stiffness, fatigue and physical function in tumour necrosis factor inhibitor-naive patients with non-radiographic axial spondyloarthritis: results from a r	15
P127 Treating rheumatoid arthritis patients with moderate disease activity: an analysis of the upadacitinib SELECT Phase III randomised studies	15
SLE disease activity stabilizes over time: a hypothesis stimulated by a model reported a few years ago and recently re-tested	15
Risk factors of impaired humoral response to COVID-19 vaccination in rituximab-treated patients	15
Cholinergic dysautonomia in a patient with systemic lupus erythematosus	15
Musculoskeletal involvement in systemic lupus erythematosus: a contrast-enhanced magnetic resonance imaging study in 107 subjects	15
Infection incidence, timing and dose dependency in rheumatoid arthritis patients treated with rituximab: a retrospective cohort study	15
Patients with rheumatoid arthritis presenting with mono- or oligo-arthritis and high VAS-ratings remain the most fatigued during 5 years of follow-up	15
Relapsing IgG4-related disease presenting with unilateral parotid mass and facial palsy	15
Toll-like receptor triggering in systemic sclerosis: time to target	15
P070 Tele-consultations from the patient’s perspective: during the pandemic and beyond	15
New prescribing recommendations bring an opportunity to focus on better reproductive health for women with rheumatic disease	15
Myelomonocytic cells in giant cell arteritis activate trained immunity programs sustaining inflammation and cytokine production	15
Belimumab is not associated with COVID-19 mRNA vaccination failure in systemic lupus erythematosus	15
P081 Unravelling SLE in a young male child	14
Comment on: Nailfold microvascular abnormalities are associated with a higher prevalence of pulmonary arterial hypertension in patients with MCTD	14
Kimura’s disease presenting as a posterior mediastinal mass complicated with relapsing polychondritis	14